Tourmaline Bio, Inc. (TRML)
(Delayed Data from NSDQ)
$28.26 USD
-0.87 (-2.99%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $28.28 +0.02 (0.07%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth A Momentum B VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
TRML 28.26 -0.87(-2.99%)
Will TRML be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for TRML based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TRML
Here's Why Momentum in Tourmaline Bio, Inc. (TRML) Should Keep going
Here's What Could Help Tourmaline Bio, Inc. (TRML) Maintain Its Recent Price Strength
TRML: What are Zacks experts saying now?
Zacks Private Portfolio Services
What Makes Tourmaline Bio, Inc. (TRML) a Good Fit for 'Trend Investing'
Other News for TRML
Piper Sandler Sticks to Its Buy Rating for Tourmaline Bio (TRML)
Tourmaline Bio management to meet with Truist
Keros Therapeutics appoints Chyung as CMO
Tourmaline Bio management to meet with Truist
Tourmaline Bio initiated with bullish view at Cantor Fitzgerald